drugset / Trial / NCT03525379

Evaluating the Clinical Efficacy of Resveratrol in Improving Metabolic and Skeletal Muscle Function in Patients With Heart Failure

NCT03525379

Phase 2 Completed 13 enrolled University of Alberta
RandomizedSequentialDouble-blindDiagnostic

Summary

This is a randomized, double-blind, placebo-controlled trial evaluating the effect of resveratrol on metabolic and skeletal muscle function. Patients will be randomized and allocated to either resveratrol or placebo, for 8 weeks with a 2-week run-in period before the intervention period (to ensure they are not on any nutritional supplement that contains resveratrol).

Timeline

Start
2017-10-26
Primary completion
2019-10-08
Completion
2019-10-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Resveratrol Small molecule Oral